Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03568188
Other study ID # 69HCL18_0292
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 28, 2018
Est. completion date September 28, 2023

Study information

Verified date October 2018
Source Hospices Civils de Lyon
Contact Sébastien CROUZET, Pr
Phone 04 72 11 03 25
Email sebastien.crouzet@chu-lyon.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the focal treatment HIFU is to destroy the cancer without causing side effects in contrast to radical treatments. Radical treatments (surgery or radiation therapy) are the standard therapies for patient with intermediate risk localized prostate cancer and good life expectancy (prostatectomy if life expectancy10 years) By destroying only the part of the gland that harbors cancer, it may indeed be possible to provide efficient cure of the disease while minimizing treatment-induced morbidity (incontinence and loss of potency). Around 20% of patients presented with a unilateral tumor: this patients are currently treated radically. No study published papers reported outcomes of a large population (>100) with intermediate risk cancers treated with Focal-HIFU (conducted with the Focal One® device). Focal therapy must be only offer within clinical trial setting (EAU (European Association of Urology) Guidelines ). The aim of this cohort will be to determine the success rate of Focal-HIFU in this intermediate risk population. The result the study will be used for calculation the arms of a future random study


Recruitment information / eligibility

Status Recruiting
Enrollment 170
Est. completion date September 28, 2023
Est. primary completion date September 28, 2020
Accepts healthy volunteers No
Gender Male
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria:

- Patient having been clearly informed of the study and having accepted, with sufficient reflection time, to participate by signing the informed consent form of the study.

- Age between 50 and 80 years with a life expectancy of more than 5 years. Patients between the ages of 75 and 80 will need to have a lower G8 score.

- Initial diagnosis of localized prostate cancer (T1 or T2a) with the following characteristics:

- A multiparametric MRI showing a single invasive tumor focus at most two contiguous sextants confirmed by biopsies (index tumor). Patients with multiple suspected MRI foci may be included if only one of these foci is confirmed by targeted biopsies.

- The tumor volume on MRI should be> 0.5 cc, ie a tumor =10 mm in its longest dimension.

- Gleason score= 7 (3+4).

- PSA = 10ng / ml.

- Patient affiliated with health insurance or beneficiary of an equivalent plan.

Exclusion Criteria:

- Contraindications to treatment with HIFU-F:

- Tumor not accessible (impossibility to apply a safety margin of 9 mm around the MRI target).

- Multiple intra prostatic calcifications inducing, on ultrasound, a shadow cone in the prostate preventing the penetration of ultrasound and thus the realization of the treatment.

- History of pelvic irradiation

- Presence of an implant (stent, catheter) located less than 1 cm from the treatment area.

- Fistula of the urinary tract or rectum.

- Anal or rectal fibrosis, anal or rectal stenosis or other abnormalities making it difficult to insert the Focal One® probe.

- Anatomical abnormality of the rectum or rectal mucosa.

- Patient with artificial sphincter, penile prosthesis or intra prostatic implant, eg stent.

- History of intestinal inflammatory pathology.

- Uro-genital infection in progress (the infection to be treated before HIFU treatment).

- Anterior surgery at the level of the anus or rectum making the introduction of the probe impossible.

- Allergy to latex.

- Thickness of the rectal wall> 10mm.

- Patient undergoing treatment for benign prostatic hyperplasia (BPH) with IPSS> 25.

- Patient with a medical contraindication to Sonovue® injection.

- Patient with a medical contraindication on MRI.

- Patient already treated for prostate cancer (hormone therapy, radiotherapy, surgery).

- History of uncontrolled cancer and / or treated for less than 5 years (with the exception of basal cell skin cancer).

- History of pelvic radiotherapy.

- History of sclerosis of the bladder neck or urethral stenosis.

- Patient at risk of bleeding according to medical advice.

- Patients with unstable neurological pathology.

- Patient who has been treated for a therapeutic trial within 30 days of enrollment or who wishes to participate in an ongoing study that may interfere with this study.

- Legal person protected by law.

- Patient not able to understand the objectives of the study or refusing to comply with postoperative instructions.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
treatment with focal HIFU
HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
Biological:
PSA dosage
PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
Device:
MRI
MRI exam will be regularly performed during patient follow up.
Other:
Questionnaires
Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function).
Procedure:
Prostatic biopsies
Prostatic biopsies will be regularly performed during patient follow up.
Biological:
blood test
if the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) will be performed during their follow up.
urine test
if the patient decides to participate in the ancillary study, a urine test (for PCA3 test) will be performed during their follow up.

Locations

Country Name City State
France Service d'Urologie, Clinique Tivoli Ducos Bordeaux
France Service d'Urologie, CHU de Guebwiller Colmar Colmar
France Service d'Urologie CHRU de Lille, Hôpital HURIEZ Lille
France Service d'Urologie Générale de Santé - Hôpital Privé La Louvière Lille
France Service d'Urologie et Chirurgie de la Transplantation, Hôpital Edouard Herriot, Lyon
France Service d'urologie Assistance Publique - Hôpitaux de Marseille - Hôpital Marseille Nord Marseille
France Département d'Urologie, Institut Montsouris Paris
France Clinique Urologique Nantes Atlantis Saint-Herblain
France Service d'Urologie, Hôpital Foch Suresnes
France CHU de Toulouse - Hôpital de Rangueil Toulouse

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary patient proportion with controlled disease (Control of the pathology) The main objective is the estimation of FOCAL HIFU treatment efficacy defined as the percentage of positive biopsies in the treated lobe at 12 months after inclusion. 12 months
Secondary proportion of patients needing additional treatment The objective is to determine the proportion of patients needing additional treatment (focal or radical) at 12 months. This includes patients who wish or require radical treatment (prostatectomy, radiotherapy), total focal treatment, or additional focal treatment. 12 months
Secondary proportion of patients needing additional treatment The objective is to determine the proportion of patients needing additional treatment (focal or radical) at 48 months. This includes patients who wish or require radical treatment (prostatectomy, radiotherapy), total focal treatment, or additional focal treatment. 48 months
Secondary proportion of patients needing additional radical treatment The objective is to determine the proportion of patients needing additional radical treatment at 12 months. This includes patients who wish or require prostatectomy or radiotherapy total focal treatment. 12 months
Secondary proportion of patients needing additional radical treatment The objective is to determine the proportion of patients needing additional radical treatment at 48 months. This includes patients who wish or require prostatectomy or radiotherapy total focal treatment. 48 months
Secondary rate of positive biopsies The rate of positive biopsies in the untreated lobe and treated lobe evaluated and will be used to evaluate the carcinologic evolution at 12 months. 12 months
Secondary rate of positive biopsies The rate of positive biopsies in the untreated lobe and treated lobe evaluated and will be used to evaluate the carcinologic evolution at 24 months. 24 months
Secondary rate of positive biopsies The rate of positive biopsies in the untreated lobe and treated lobe evaluated and will be used to evaluate the carcinologic evolution at 48 months. 48 months
Secondary clinically significant cancer rate The clinically significant cancer rate (Gleason 7 or invasion of more than 3 biopsies or invasion> 3 mm regardless of Gleason) in the untreated lobe and the treated lobe will be measured and will be used to evaluate the carcinologic evolution at 48 months. 48 months
Secondary Gleason score Evolution of the Gleason score (appearance of Gleason =7) will be measured and will be used to evaluate the carcinologic evolution at 12 month.
The Gleason score is a prognosis factor for prostate cancer. It is based prostate cancer cells architecture from biopsies. The more the architectures of prostate cancer cell is destroyed, the worse is the prognosis. The score grades from 3 to 5, 5 being the more destroyed, the score 1 and 2 being normal cells. When there is more than one tumor cells population in the prostate, the score is composed of the sum of the most 2 frequents grade. For example a Gleason 7 tumor could be 3+4 or 4+3, the 4+3 being more aggressive.
12 months
Secondary Gleason score Evolution of the Gleason score (appearance of Gleason =7) will be measured and will be used to evaluate the carcinologic evolution at 24 month.
The Gleason score is a prognosis factor for prostate cancer. It is based prostate cancer cells architecture from biopsies. The more the architectures of prostate cancer cell is destroyed, the worse is the prognosis. The score grades from 3 to 5, 5 being the more destroyed, the score 1 and 2 being normal cells. When there is more than one tumor cells population in the prostate, the score is composed of the sum of the most 2 frequents grade. For example a Gleason 7 tumor could be 3+4 or 4+3, the 4+3 being more aggressive.
24 months
Secondary Gleason score Evolution of the Gleason score (appearance of Gleason =7) will be measured and will be used to evaluate the carcinologic evolution at 48 month.
The Gleason score is a prognosis factor for prostate cancer. It is based prostate cancer cells architecture from biopsies. The more the architectures of prostate cancer cell is destroyed, the worse is the prognosis. The score grades from 3 to 5, 5 being the more destroyed, the score 1 and 2 being normal cells. When there is more than one tumor cells population in the prostate, the score is composed of the sum of the most 2 frequents grade. For example a Gleason 7 tumor could be 3+4 or 4+3, the 4+3 being more aggressive.
48 months
Secondary Appearance of another cancerous focus in the other half of the prostate Appearance of another cancerous focus in the other half of the prostate will be supervised and will be used to evaluate the carcinologic evolution at 12 months. 12 months
Secondary Appearance of another cancerous focus in the other half of the prostate Appearance of another cancerous focus in the other half of the prostate will be supervised and will be used to evaluate the carcinologic evolution at 24 months. 24 months
Secondary Appearance of another cancerous focus in the other half of the prostate Appearance of another cancerous focus in the other half of the prostate will be supervised and will be used to evaluate the carcinologic evolution at 48 months. 48 months
Secondary Appearance of metastases Appearance of metastases (lymph node or bone) will be supervised and will be used to evaluate the carcinologic evolution at 12 months. 12 months
Secondary Appearance of metastases Appearance of metastases (lymph node or bone) will be supervised and will be used to evaluate the carcinologic evolution at 24 months. 24 months
Secondary Appearance of metastases Appearance of metastases (lymph node or bone) will be supervised and will be used to evaluate the carcinologic evolution at 48 months. 48 months
Secondary Appearance of an extra capsular extension Appearance of an extra capsular extension will be supervised and will be used to evaluate the carcinologic evolution at 12 months. 12 months
Secondary Appearance of an extra capsular extension Appearance of an extra capsular extension will be supervised and will be used to evaluate the carcinologic evolution at 24 months. 24 months
Secondary Appearance of an extra capsular extension Appearance of an extra capsular extension will be supervised and will be used to evaluate the carcinologic evolution at 48 months. 48 months
Secondary Overall survival Overall survival at 48 months will be measured from the date of inclusion to the date of death, all causes of death combined or the date of last new or point date to 48 months. 48 months
Secondary Prostate cancer specific survival Prostate cancer specific survival at 48 months will be measured from the date of inclusion to the date of death related to prostate cancer or the date of last new or point date to 48 months 48 months
Secondary Recurrence free survival Prostate cancer specific survival at 48 months will be measured from the date of inclusion to the date of first metastasis , or the date of last new or point date to 48 months. 48 months
Secondary Proportion of serious adverse effect comparison between the 2 groups of the proposition of serious adverse effect at 48 months 48 months
Secondary Quality of life score quality of life will be assessed using the QLQC30 (Quality of Life questionnaire) questionnaire.
It is a specific questionnaire to determine the quality of life a patient with cancer. It is composed of 30 questions with 4 potential answers going from: not at all, a little, enough or a lot, within 28 questions and with a visual scale going from 1 to 7 (7 being excellent and 1 being very bad) for the last 2 questions. The raw score is established by adding the score of each question and a linear transformation range it from 0 to 100. The higher the score, the better the quality of life.
over the 48 months
Secondary EPIC-26 score urinary function will be assessed using the EPIC-26 (The Expanded Prostate Cancer Index Composite) questionnaire.
The EPIC-26 is a self-reported scale health-related quality of life questionnaire for prostate cancer patients . It is composed of 26 items in 4 different domains: urinary incontinence, urinary irritation/obstruction, bowel, sexual, and vitality/hormonal.
Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale. Each items as a standardized value from 0 to 100. Then the average of the standardized value is determined in each domain to crate the summary score. The higher the score, the better the quality of life.
over the 48 months
Secondary IPSS score urinary function will be assessed using the IPSS (International Prostate Score Symptom) questionnaire.
The IPSS questionnaire is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the patient to choose one out of six answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35. The score is then categorized as follow: Mild (symptoms score less than or equal to 7), Moderate (symptom score range 8-19), Severe (symptom score range 20-35). The higher the score, the worse the symptoms.
over the 48 months
Secondary IIEF-5 score Sexual function will be assessed using the IIEF-5 (The International Index of Erectile Function) questionnaire.
The IIEF-5 Questionnaire is composed of 5 items with 5 possible answers rating from 1 to 5 (very low, low, moderate, high, very high).
The score is the sum of the ordinal responses to the 56 items. It is then categorized as follow: 22-25: No erectile dysfunction, 17-21: Mild erectile dysfunction, 12-16: Mild to moderate erectile dysfunction, 8-11: Moderate erectile dysfunction, 5-7: Severe erectile dysfunction. The higher the score, the better the sexual function.
over the 48 months
Secondary patient proportion with controlled disease (Control of the pathology) The main objective is the estimation of FOCAL HIFU treatment efficacy defined as the percentage of positive biopsies in the treated lobe at 48 months after inclusion. 48 months
Secondary Ancillary study: Measure of anti-tumoral immunity induction The consequences of HIFU treatment over immune anti-tumoral induction will be estimated by the description of Programmed death-ligand 1/ligand 2 (PDL1/L2) overexpression on immune cells and overexpression of Programmed cell death 1 (PD-1) on T lymphocytes (T-cells). over the 48 months
Secondary Ancillary study: Measure of Circulating Tumor Cells (CTC) number reduction The consequences of HIFU treatment over Messenger RNA (mRNA) will be estimated by measure of CTC number reduction. over the 48 months
Secondary Ancillary study: Measure of ncRNA (non-coding RNA) PCA3 (Prostate cancer gene 3) level reduction. The consequences of HIFU treatment over PCA3 will be estimated by measure of ncRNA PCA3 level reduction. over the 48 months
See also
  Status Clinical Trial Phase
Recruiting NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A
Recruiting NCT03668652 - Focal Prostate Ablation Versus Radical Prostatectomy N/A
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A
Terminated NCT00953576 - Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer Phase 1/Phase 2
Recruiting NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Recruiting NCT03543189 - Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy Phase 1/Phase 2
Active, not recruiting NCT00779168 - White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy Phase 1
Recruiting NCT02799706 - Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer Phase 3
Recruiting NCT01990196 - Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer Phase 2
Completed NCT02124668 - A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Phase 2
Recruiting NCT03327675 - High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer N/A
Active, not recruiting NCT01420250 - Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer Phase 1
Recruiting NCT03440879 - Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose N/A